Burning Rock Biotech Ltd. · NASDAQ:BNR
Burning Rock Biotech — Q3 2020 Earnings Presentation
22 slides from Burning Rock Biotech's earnings presentation, November 2020
Slide 1: Burning Rock Biotech Limited 3Q20 Updates
Burning Rock Biotech Limited 3Q20 Updates Nasdaq listed since Jun 2020, BNR US Equity
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Burning Rock Biotech Limited (the “Company”) solely for information purpose and has not been independently verified. No representations, warranties or undertakings, express or implied, are made by the Company or any of its affiliates, advisers, or re
Slide 3: What we do
What we do China’s molecular diagnostics leader for precision oncology Early Detection $29bn TAM Therapy Selection & MRD $4.5bn TAM 3
Slide 4: Our focus
Our focus Therapy Selection Early Detection • Expand leadership in the China market, • Be at the forefront of global R&D on blood- based on product performance and quality, based pan-cancer early detection, through for both tissue- and liquid-based NGS testing in-house R&D and clinical collaboration
Slide 5: Our team
Our team Yusheng Han Shannon Shaokun Chuai, Ph.D. Joe Zhihong Zhang, Ph.D. Founder, Chairman, CEO Director, Chief Operating Officer Chief Technology Officer Leo Li Hao Liu Director, Chief Financial Officer Chief Medical Officer 5
Slide 6: Today's topics
Today’s topics • Product roadmap update Early Detection • 6-cancer test validation data released at ESMO Asia Virtual Congress 2020 • MagnisBR analytical validation data released at Association for Molecular Therapy Pathology (AMP) Annual Meeting Selection • Myriad myChoice HRD test in-licensing • 3
Slide 7: Burning Rock early detection technology – ELSA-Seq
Burning Rock early detection technology – ELSA-Seq R&D started in 2016 Combination of targeted deep methylation sequencing and machine learning Technology Highlights: • Single-stranded library prep starts as low as 1ng cfDNA • Bisulfite conversion or enzymatic conversion compatible • Intelligent pro
Slide 8: Early detection product development roadmap
Early detection product development roadmap Latest progress – expanded from 3 to 6 cancer types with improved specificity Proof-of-concept • Completed. Results released at AACR 2019 Single-cancer • Lung cancer, proof of concept on assay and bioinformatics methodology 2019 • Manuscript on methodology
Slide 9: Clinical progress
Clinical progress ~5.5 million CpG sites ~450,000 CpG sites Marker discovery LC/CRC/LIHC/OVCA/PAAD/ESCA TCGA & GEO database (tissue) ~160,000 CpG sites Panel validation LC/CRC/LIHC/OVCA/PAAD/ESCA/Control (tissue and blood) Assay validation Training Set Validation Set Additional (blood) LC CRC LIHC L
Slide 10: Overview of training and validation sets
Overview of training and validation sets Comparable cancer and non-cancer groups Training Control Cancer LC CRC LIHC OVCA PAAD ESCA total 195 274 50 46 48 50 40 40 age, mean+/-SD 53+/-6 57+/-8 60+/-6 60+/-8 55+/-8 50+/-8 59+/-7 57+/-6 age, min/max 40/72 40/75 47/74 44/75 43/72 40/73 42/71 45/70 sex,
Slide 11: Sensitivity
Our test detects cancers at early stage with high specificity and high sensitivity Sensitivity Clinical Stages（# in Training / # in Validation） • The specificity was 99.5% (95%CI: 96.7-100%; training) and 98.3% (95%CI: 95.8-99.4%; validation). • The sensitivity was 79.9% (95%CI: 74.6-84.4%; training
Slide 12: Our test detects cancers at early stage with high specificity and sensitivity
Our test detects cancers at early stage with high specificity and high sensitivity Training Validation Training Validation 12
Slide 13: Our test predicts the tissue of origin with high accuracy
Our test predicts the tissue of origin with high accuracy • The classifier was able to distinguish different cancer tissue samples with exceptional accuracy (129/131). • 98.6% of detected cancer blood samples were assigned an organ-source in both training and validation sets: o For single organ call
Slide 14: Today's topics
Today’s topics • Product roadmap update Early Detection • 6-cancer test validation data released at ESMO Asia Virtual Congress 2020 • MagnisBR analytical validation data released at Association for Molecular Therapy Pathology (AMP) Annual Meeting Selection • Myriad myChoice HRD test in-licensing • 3
Slide 15: Magnis BR: a turn-key solution for hospitals
Magnis BR: a turn-key solution for hospitals 1 Magnis BR Current Manual Process Co-developed with Agilent; BR proprietary chemistry Manual Total End Repair 20min 1h20min Extraction Adapter 2 Ligation & 30min 1h20min Purification Pre-Library Amp. & Purification 40min 1h20min & QC Library Prep Fully I
Slide 16: Analytical Validation of Magnis BR Assay
Analytical Validation of Magnis BR Assay OncoScreen IO Tissue assay OncoCompass Target cfDNA Assay In 16 clinical FFPE samples. In 34 Clinical cfDNA The concordance rate for total samples, the concordance 717 variants was 98.7%, and rate for total 120 variants vv 100% for MSI status (Jaccard was 97.
Slide 17: Myriad myChoice HRD test in-licensing
Myriad myChoice® HRD test in-licensing measures a phenotype of genomic instability associated with HRD FDA CDx approval: tBRCAm and/or genomic instability score (GIS) ≥ 42 Drug and Cancer Indication Trial and Approval Date Olaparib (AZ) First-line maintenance treatment of HRD- PAOLA-1, May 8, 2020 O
Slide 18: Myriad myChoice HRD in-licensing
Myriad myChoice® HRD in-licensing • Immediately addressable market (on-label use): first-line aOC patients with maintenance therapy: ~10000-15000 annually • Drugs and cancer types being studied using myChoice ® HRD as a companion or exploratory biomarker: ü Olaparib: HER2- breast cancer ü Niraparib:
Slide 19: Today's topics
Today’s topics • Product roadmap update Early Detection • 6-cancer test validation data released at ESMO Asia Virtual Congress 2020 • MagnisBR analytical validation data released at Association for Molecular Therapy Pathology (AMP) Annual Meeting Selection • Myriad myChoice HRD test in-licensing • 3
Slide 20: Operating metrics
Operating metrics 2018 2019 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 # of ordering hospitals 263 335 249 265 281 304 232 284 289 Central- # of ordering physicians 1,135 1,632 984 1,059 1,155 1,222 810 1,175 1,194 lab channel # of patients tested1 15,821 23,075 5,336 6,047 6,769 7,576 4,680 7,252 8,644 YoY
Slide 21: Financials
Financials 18 19 1Q20 2Q20 3Q20 3Q20 2020 RMB millions 2019 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 YoY YoY YoY YoY YoY QoQ Guide Revenue 381.7 88% 83% 104.5 84.8 103.7 88.7 67.3 107.0 123.9 -36% 26% 19% 16% 420 Central lab 276.3 83% 71% 72.8 63.4 69.3 70.8 46.1 74.6 89.9 -37% 18% 30% 21% In-hospital 87.
Slide 22: Appendix: 6-cancer test sensitivity by cancer type and stage
Appendix 6-cancer test sensitivity by cancer type and stage Sensitivity and Specificity - Correct#/Total# (%) Cancer Group I II III IV Overall Train 10/20 (50.0) 10/14 (71.4) 4/7 (57.1) 8/9 (88.9) 32/50 (64.0) Lung Test 6/16 (37.5) 12/16 (75.0) 9/14 (64.3) 14/15 (93.3) 41/61 (67.2) Train 7/9 (77.8)